IMRX Valuation

Immuneering Corp

Add to Watchlist

Advanced Chart

5.750

+0.15(2.679%)1D

Overview
Forecast
Valuation
Earnings

IMRX Relative Valuation

IMRX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, IMRX is overvalued; if below, it's undervalued.

Historical Valuation

Immuneering Corp (IMRX) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -3.87. The fair price of Immuneering Corp (IMRX) is between NaN to NaN according to relative valuation methord.

Relative Value

Fair Zone

NaN-NaN

Current Price：5.75

Fair

-3.54

Trailing

Forward

0.00

EV/EBITDA

Immuneering Corp. (IMRX) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -2.13. The thresholds are as follows: Strongly Undervalued below -9.77, Undervalued between -9.77 and -5.95, Fairly Valued between 1.68 and -5.95, Overvalued between 1.68 and 5.50, and Strongly Overvalued above 5.50. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-2.09

EV/EBIT

Immuneering Corp. (IMRX) has a current EV/EBIT of -2.09. The 5-year average EV/EBIT is -2.24. The thresholds are as follows: Strongly Undervalued below -10.12, Undervalued between -10.12 and -6.18, Fairly Valued between 1.70 and -6.18, Overvalued between 1.70 and 5.64, and Strongly Overvalued above 5.64. The current Forward EV/EBIT of -2.09 falls within the Historic Trend Line -Fairly Valued range.

0.00

Immuneering Corp. (IMRX) has a current PS of 0.00. The 5-year average PS is 312.97. The thresholds are as follows: Strongly Undervalued below -1345.80, Undervalued between -1345.80 and -516.42, Fairly Valued between 1142.35 and -516.42, Overvalued between 1142.35 and 1971.73, and Strongly Overvalued above 1971.73. The current Forward PS of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-2.24

P/OCF

Immuneering Corp. (IMRX) has a current P/OCF of -2.24. The 5-year average P/OCF is -2.47. The thresholds are as follows: Strongly Undervalued below -10.79, Undervalued between -10.79 and -6.63, Fairly Valued between 1.69 and -6.63, Overvalued between 1.69 and 5.85, and Strongly Overvalued above 5.85. The current Forward P/OCF of -2.24 falls within the Historic Trend Line -Fairly Valued range.

-2.53

P/FCF

Immuneering Corp. (IMRX) has a current P/FCF of -2.53. The 5-year average P/FCF is -1.33. The thresholds are as follows: Strongly Undervalued below -4.13, Undervalued between -4.13 and -2.73, Fairly Valued between 0.06 and -2.73, Overvalued between 0.06 and 1.46, and Strongly Overvalued above 1.46. The current Forward P/FCF of -2.53 falls within the Historic Trend Line -Fairly Valued range.

Immuneering Corp (IMRX) has a current Price-to-Book (P/B) ratio of 7.15. Compared to its 3-year average P/B ratio of 1.72 , the current P/B ratio is approximately 316.12% higher. Relative to its 5-year average P/B ratio of 1.55, the current P/B ratio is about 360.60% higher. Immuneering Corp (IMRX) has a Forward Free Cash Flow (FCF) yield of approximately -24.68%. Compared to its 3-year average FCF yield of -57.13%, the current FCF yield is approximately -56.80% lower. Relative to its 5-year average FCF yield of -45.59% , the current FCF yield is about -45.87% lower.

7.15

P/B

Median3y

1.72

Median5y

1.55

-24.68

FCF Yield

Median3y

-57.13

Median5y

-45.59

Competitors Valuation Multiple

The average P/S ratio for IMRX's competitors is 6.03, providing a benchmark for relative valuation. Immuneering Corp Corp (IMRX) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Aclaris Therapeutics Inc

Theratechnologies Inc

Ironwood Pharmaceuticals Inc

Sellas Life Sciences Group Inc

Performance Decomposition

Market capitalization of IMRX increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of IMRX in the past 1 year is driven by Unknown.